Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Homo sapiens | polymerase (DNA directed), beta | Starlite/ChEMBL | No references |
Mus musculus | RAR-related orphan receptor gamma | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma cruzi | mitochondrial DNA polymerase beta-PAK, putative | polymerase (DNA directed), beta | 335 aa | 303 aa | 32.3 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | glutaminase DH11.1 | 0.0286 | 0.7601 | 1 |
Loa Loa (eye worm) | TAR-binding protein | 0.0126 | 0.2733 | 0.3595 |
Leishmania major | mitochondrial DNA polymerase beta-PAK, putative | 0.0173 | 0.4162 | 0.155 |
Trypanosoma brucei | monoglyceride lipase, putative | 0.0137 | 0.3092 | 0.2747 |
Trypanosoma brucei | mitochondrial DNA polymerase beta | 0.0365 | 1 | 1 |
Mycobacterium ulcerans | glutaminase | 0.0286 | 0.7601 | 1 |
Plasmodium vivax | PST-A protein | 0.0137 | 0.3092 | 0.5 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0126 | 0.2733 | 0.3595 |
Trichomonas vaginalis | glutaminase, putative | 0.0286 | 0.7601 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0126 | 0.2733 | 0.3595 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0052 | 0.0501 | 0.0659 |
Mycobacterium ulcerans | hypothetical protein | 0.0192 | 0.4755 | 0.3689 |
Trypanosoma brucei | mitochondrial DNA polymerase beta-PAK | 0.0173 | 0.4162 | 0.3871 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta, putative | 0.0365 | 1 | 1 |
Plasmodium falciparum | lysophospholipase, putative | 0.0137 | 0.3092 | 0.5 |
Trypanosoma brucei | monoglyceride lipase, putative | 0.0137 | 0.3092 | 0.2747 |
Schistosoma mansoni | tar DNA-binding protein | 0.0126 | 0.2733 | 0.3595 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0126 | 0.2733 | 0.3595 |
Entamoeba histolytica | hydrolase, alpha/beta fold family domain containing protein | 0.0137 | 0.3092 | 0.5 |
Brugia malayi | RNA binding protein | 0.0126 | 0.2733 | 0.3595 |
Loa Loa (eye worm) | glutaminase | 0.0286 | 0.7601 | 1 |
Trypanosoma cruzi | monoglyceride lipase, putative | 0.0137 | 0.3092 | 0.2747 |
Loa Loa (eye worm) | glutaminase 2 | 0.0286 | 0.7601 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0126 | 0.2733 | 0.5 |
Plasmodium falciparum | esterase, putative | 0.0137 | 0.3092 | 0.5 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta-PAK, putative | 0.0173 | 0.4162 | 0.3871 |
Schistosoma mansoni | tar DNA-binding protein | 0.0126 | 0.2733 | 0.3595 |
Mycobacterium leprae | POSSIBLE LYSOPHOSPHOLIPASE | 0.0137 | 0.3092 | 0.5 |
Loa Loa (eye worm) | RNA binding protein | 0.0126 | 0.2733 | 0.3595 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0192 | 0.4755 | 1 |
Echinococcus multilocularis | tar DNA binding protein | 0.0126 | 0.2733 | 0.5 |
Plasmodium falciparum | lysophospholipase, putative | 0.0137 | 0.3092 | 0.5 |
Toxoplasma gondii | hypothetical protein | 0.0059 | 0.0705 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0126 | 0.2733 | 0.3595 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta, putative | 0.0365 | 1 | 1 |
Plasmodium falciparum | lysophospholipase, putative | 0.0137 | 0.3092 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0052 | 0.0501 | 0.0659 |
Schistosoma mansoni | tar DNA-binding protein | 0.0126 | 0.2733 | 0.3595 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta-PAK, putative | 0.0062 | 0.0817 | 0.0358 |
Entamoeba histolytica | hydrolase, alpha/beta fold family domain containing protein | 0.0137 | 0.3092 | 0.5 |
Brugia malayi | TAR-binding protein | 0.0126 | 0.2733 | 0.3595 |
Schistosoma mansoni | glutaminase | 0.0286 | 0.7601 | 1 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0052 | 0.0501 | 0.0659 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0052 | 0.0501 | 0.0659 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 0.0794 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 3.9811 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of DNA Polymerase Beta. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 6.3096 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 19.9526 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488771] | ChEMBL. | No reference |
Potency (functional) | 112.2018 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | ||
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.